We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division

DIASORIN MOLECULAR

DiaSorin Molecular LLC manufactures and distributes innovative molecular diagnostic products on the versatile LIAISON... read more Featured Products: More products

Download Mobile App





Diasorin Launches New Assay for Rapid Identification of SARS-CoV-2 Variants

By LabMedica International staff writers
Posted on 25 May 2021
Print article
Image: Diasorin Launches New Assay for Rapid Identification of SARS-CoV-2 Variants (Photo courtesy of DiaSorin Molecular LLC)
Image: Diasorin Launches New Assay for Rapid Identification of SARS-CoV-2 Variants (Photo courtesy of DiaSorin Molecular LLC)
DiaSorin Molecular LLC (‎Cypress, CA, USA) has released the Simplexa SARS-CoV-2 Variants Direct assay (RUO) to enable detection and discrimination of four SARS-CoV-2 mutations associated with circulating virus variants without requiring upfront RNA extraction.

The assay helps to streamline and speed-up the pre-selection process of positive samples that need further sequencing, maximizing the effectiveness of monitoring programs for the spread of concerning variants. The Simplexa SARS-CoV-2 Variants Direct is a Research Use Only assay and is not for use in diagnostics procedures. The assay allows for the in vitro qualitative differential detection of the mutations N501Y, E484K, E484Q, and L452R directly from nasopharyngeal and nasal swab specimens from individuals previously diagnosed with COVID-19. These mutations are present in potential variants of clinical interest including those that were isolated in the UK (B.1.1.7), South Africa (B.1.351), Brazil/Japan (P.1 and P.2), New York (B.1.526/B.1.526.1), California (B.1.427/B.1.429), Nigeria (B.1.525) and India (B.1.617/B.1.617.1/B.1.617.2/B.1.617.3).

The kit format consists of pre-aliquoted reagents that are ready for use while leveraging Direct Amplification Disc technology and the melting curve capabilities of the LIAISON MDX. During the course of the COVID-19 pandemic, new genetic variants of SARS-CoV-2 have spread rapidly across the globe, creating concern as to their infectivity, transmissibility, and the impact on current vaccines or available immunotherapy. The availability of affordable molecular solutions that can be easily implemented and provide quick results will facilitate and increase the ability to monitor the spread of variants by streamlining laboratory workflows.

“The ability to identify potential SARS-CoV-2 variants in positive samples is of national and global importance in the continuous effort to monitor, track, and fight against SARS-CoV-2 variants,” said John Gerace, president of DiaSorin Molecular. “We are proud to continually develop products that meet the evolving needs of laboratories around the globe during this time.”




Gold Supplier
Sample Transport
VACUETTE Transport Line
New
Silver Supplier
Remote Lab Review Software
CellaVision Remote Review Software
New
Influenza A/B Assay
Influenza A+B One Step Assay
New
Silver Supplier
SARS-CoV-2 qRT-PCR IVD Reagent Kit
SARS-CoV-2 qRT-PCR Dx Kit (CE-IVD)

Print article
BIOHIT  Healthcare OY

Channels

Industry

view channel
Image: Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device (Photo courtesy of Quidel Corporation)

Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device

Quidel Corporation (San Diego, CA, USA) has received an amended Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) allowing the company to market Sofia Q, its latest addition... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.